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BACKGROUND: Denmark has poorer 5-year survival rates than many other Western European countries, and cancer patients tend to
have more advanced stages at diagnosis than those in other Scandinavian countries. Part of this may be due to delay in diagnosis. The
aim of this paper is to give an overview of the initiatives currently underway to reduce delays.
METHODS: Description of Danish actions to reduce delay.
RESULTS: Results of surveys of patient-, doctor- and system-related delays are presented and so are the political initiatives to ensure
that cancer is seen as an acute disease.
CONCLUSION: In future, fast-track diagnosis and treatment will be provided for suspected cancers and access to general diagnostic
investigations will be improved. A large national experiment with cancer seen as an acute disease is currently being implemented, and
as yet the results are unknown.
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The findings from the EUROCARE studies suggest that Denmark,
like the United Kingdom, has poorer 5-year survival rates across a
range of cancer types than other Western European countries
(Sant et al, 2001; Karim-Kos et al, 2008; Berrino et al, 2009;
Verdecchia et al, 2009). Mortality rates from cancer are also high
in Denmark (International Agency for Research on Cancer, 2007).
These findings led to a major public debate and a sense of
disappointment regarding Danish efforts to control cancer. As a
result, a National Cancer Steering Group was established in 1998,
chaired by the National Board of Health with representation from
all relevant specialties. National Cancer Plans were developed by
this steering group in 2000 and 2005, which analysed the possible
problems and made recommendations in relation to prevention,
diagnosis and treatment.
Cancer incidence in Denmark is relatively high, reflecting
lifestyle factors, for example, a relatively high prevalence of
smoking (44% of the population in 1987, and 34% in 2000 were
daily smokers) (Ekholm et al, 2006). As a result, initiatives were
launched to reduce smoking, increase exercise, promote healthier
diets and reduce excessive exposure to ultraviolet light. A cervical
screening programme had been running for several decades.
Following the Cancer Plan in 2005, a national breast cancer
screening programme was established. In 2008, a decision was
made to set up a colorectal cancer screening programme, but this
has not yet been implemented. To improve treatment, necessary
but politically difficult decisions had to be taken to concentrate
cancer-related surgical procedures in fewer hospital centres
(Gøtrik and Hansen, 2001).
Another problem to be tackled was that Danish cancer patients
seemed to have more advanced stages at diagnosis than those in
other Scandinavian countries (Association of the Nordic Cancer
Registries, 2007; Berrino et al, 2009). This may have been due to
bottlenecks at different stages of the clinical pathway with long
waits from first symptom to start of treatment. The second Danish
National Cancer Plan addressed these issues, recommending pre-
planned, well-structured clinical pathways without unnecessary
waiting times for investigations and procedures.
This paper provides:
  an overview of the Danish healthcare system to help understand
where delays may occur;
  a brief summary of what is known about different phases of
delay for cancer patients and
  an outline of the actions currently being undertaken to reduce
delays.
THE DANISH HEALTHCARE SYSTEM
Denmark has a tax-financed healthcare system with free access to
medical advice and treatment in general practices and hospitals.
All general practitioners (GPs) in Denmark are independent
contractors with the public health service (through the regional
health authorities) and are remunerated on a mixed fee for service
and capitation basis.
Almost all (98%) citizens (Olivarius et al, 1997) are registered
with a particular general practice, which they have to consult. List
size is on average 1550 patients per GP (including children). GPs
act as gate-keepers to investigations and hospital referrals. When a
patient experiences symptoms, the patient contacts the GP. The GP
then decides whether he/she suspects cancer (or other serious
illness). The GP may do some simple blood tests, refer the patient
for investigations at a hospital (retaining responsibility for the
patient) or refer the patient to a hospital department (at which
point the patient is no longer the responsibility of the GP).
PHASES OF THE CLINICAL PATHWAY
The pathway from first symptom to treatment can be divided into
phases as shown in Figure 1. We defined the three main time *Correspondence: Dr F Olesen; E-mail: fo@alm.au.dk
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questions arise in each of these time periods:
  Patient delay – does the patient interpret signs and symptoms
appropriately and react in a timely way?
  GP delay – does the GP explore the patient’s history appro-
priately, considering the possibility of cancer?
  System delay – is there a fast and efficient clinical pathway from
the moment investigations and/or referral is initiated by the GP
until diagnosis is confirmed or rejected and treatment is
commenced?
EVIDENCE RELATED TO CANCER DELAYS IN
DENMARK
An analysis of waiting times for 92 patients with lung cancer was
undertaken for a PhD thesis (Bjerager, 2006; Bjerager et al, 2006).
This was based on an audit of medical records, discharge letters
and interviews with GPs. This showed that the main contributors
to delay were false-negative chest X-rays and non-specific
symptoms (Figure 2). Median delay in primary care (i.e. from
first contact with a GP to referral to hospital) was 33 days
(interquartile interval 12–68 days). These findings raised two
questions: is the general clinical pathway too slow, and do we lack
appropriate strategies for patients where preliminary investiga-
tions are negative and where there are non-specific or un-
characteristic symptoms rather than alarming signs of cancer? A
second study undertaken for a PhD thesis raised even more doubts
about the organisation of the clinical diagnostic pathway (Hansen,
2008). This thesis was based on patient- and GP-reported delay for
more than 2000 consecutive incident cancer patients with all
cancer types in the former Aarhus County (population 640000;
with around 3000 new cancer cases per annum). The extent of the
different phases of delay is shown in Figure 3 and Table 1. These
show that system delay, but also patient delay, is a major
contributor to total delay. Further analysis indicated that around
half of all cancer patients presented with non-specific or atypical
symptoms, which complicated and delayed the diagnostic pathway
(data not shown).
ACTIVITIES TO REDUCE DELAYS
Activities to reduce cancer delays in Denmark can roughly be
divided into two time periods: before and after March 2007, when
the data set out above were released at a conference for politicians
and decision makers held by the Danish Cancer Society.
During the 1990s, there was increasing general awareness about
long hospital waiting times. In response to this, a law was passed in
2001 stating a 2-week waiting time guarantee from diagnosis to
treatment. However, there were no guarantees on waiting times for
investigations, for example, X-rays ordered by a GP, or for
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Figure 2 (A and B) Delay in primary healthcare for 87 consecutive
patients in Aarhus County, Denmark with a histologically verified lung
cancer diagnosed during two periods of 2003. The patients with the
shortest delay are shown in the left part of the x-axis and those with the
longest delay are shown in the right part of the x-axis. Data were based on
audit of GP records, referrals, discharge letters and interviews with GPs and
patients. Red columns (A) are cases where patients presented atypical
symptoms without direct suspicion of lung cancer. Green columns (B) are
cases where a false-negative chest X-ray contributed to the delay. For
details see Bjerager (2006).
Delay in diagnosis: the experience in Denmark
F Olesen et al
S6
British Journal of Cancer (2009) 101(S2), S5–S8 & 2009 Cancer Research UKinvestigations after GP referral to specialists working outside
hospitals. Two pre-existing trends were worsened and a new main
trend in waiting time patterns followed this initiative. First, we
observed a tendency towards ‘double gate-keeping’, where the GP
has to refer to a specialist who then gate-keeps again before
recommending special investigations (e.g. a computed tomography
scan for suspected lung cancer in a patient with a negative chest X-
ray). Second, delays of many weeks occurred when a GP requested
investigations at a hospital, rather than referring the patient for a
specialist opinion at a hospital. Third, delays in hospital from first
investigation to final diagnosis increased, as no standard or
guarantee had been set for the time from first referral to start of
treatment.
In the years following 2000, the problems became more apparent
both to clinicians and the lay population. The second Cancer Plan
recommended cancer packages with fast track from referral to
diagnosis in patients with suspected cancer, but this never became
a widespread reality.
Then, during the summer of 2007, following the presentation of
the data on different phases of delay, the press presented
numerous case stories of unacceptable clinical pathways from
symptom to diagnosis. The Danish Cancer Society suggested a new
model, making it clear that ‘cancer should be seen as an acute
disease’. In the autumn of 2007, the government and Danish
Regions (the hospital owners) launched a new diagnostic strategy.
The key components of this are:
  Cancer should be dealt with as an acute condition. If the GP or
another doctor suspects cancer, only medically necessary
waiting times should be accepted in the clinical pathway from
symptom to treatment.
  Danish Regions established the service target that a patient
should be seen within 2 days following a GP referral with
suspicion of cancer.
  Multidisciplinary working groups, chaired by the National
Board of Health, were established to describe the ideal clinical
pathway for each of the common cancer types. These included
maximum acceptable waiting times at each phase of the pathway
beginning from the time of referral.
  The government gave the National Board of Health the task of
measuring and reporting waiting times.
  A commitment was made to reduce bottlenecks in GP access to
diagnostic investigations and to help GPs in difficult cases.
  A commitment was made to invest in necessary equipment.
By spring 2009, the multidisciplinary groups had described fast
track referrals for diagnosis and treatment of the common cancers.
Strategies are being developed for managing the many patients
Table 1 Delay in days and specification of proportion (%) of patients with delay 43, 6 and 12 months for consecutive incident cancers of all types
sampled from the regional Hospital Discharge Registry in Aarhus County from 1 September 2004 to 31 August 2005
Patient delay Doctor delay System delay Total delay
Median (IQI) 21 days (7–56 days) 0 days (0–2 days) 55 days (32–93 days) 98 days (57–168 days)
% of patients with delay 43 months 15.3% 3.5% 25.8% 53.7%
% of patients with delay 46 months 6.8% 1.6% 7.5% 21.5%
% of patients with delay 41 year 2.8% 0.5% 2.6% 8.7%
Abbreviation: IQI¼interquartile interval.
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Figure 3 (A–D) Delay according to questionnaires to GPs for consecutive incident cancers of all types sampled from the regional Hospital Discharge
Registry in Aarhus County from 1 September 2004 to 31 August 2005. For definitions of delay see Figure 1. Delay over 1 year is set to 365 days. For details
see Hansen (2008).
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Substantial investments in diagnostic and therapeutic hardware
are currently being made. All regions are considering ways to
ensure sufficient support for GPs.
We still lack exact figures for the effect of all these efforts.
However, preliminary data from Danish Regions, from The
National Board of Health and from independent research
institutions show reductions in delays. It is, however, too early
to predict final data on reduction in delay in a steady state
situation when all the efforts have been implemented. Most
importantly, optimism among professionals and lay people is
increasing with regard to the prospects of achieving medical
excellence.
Initiatives to improve continuing medical education (CME) for
GPs have also been undertaken, though surprisingly a survey showed
no relation between GP-related doctor delay and the amount of CME
undertaken in the years before the survey (Hansen, 2008).
As no formal initiatives have yet been undertaken to reduce
patient delay, though the considerable public debate may have
raised awareness, systematic research into patient and doctor delay
is urgently needed. The Danish Cancer Society and the Novo
Nordisk Foundation have recently announced a 30 million DKK
(d4 million GBP) grant for further research into the period from
first symptom to diagnosis. The government is now under pressure
to put public money into this area of research, and in spring 2009,
the Department of Health announced its intention to launch a
Cancer Plan III in 2010 with anticipated substantial initiatives for
awareness and early detection.
CONCLUSION
In conclusion, a large national experiment to reduce delays and
thereby improve survival rates is now underway. As yet, the results
are unknown. However, there is a general impression that the
efforts made have increased public satisfaction with the healthcare
system’s management of serious disease. There is also an
increasing political awareness that waiting times are unacceptable
to patients who present with symptoms that might be due to
serious disease.
Future research into the reasons for different types of delay for
each cancer type is urgently needed. In particular, this should
focus on the ‘tail’ of delay where patients have very long delays
(see Figures 2 and 3). Such research should guide improvement of
clinical pathways to provide insights for provision of seamless
cancer pathways by publicly funded healthcare systems.
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